Vaccinex, Inc. VCNX

VCNX Company Overview

Vaccinex, Inc. is a clinical-stage biotechnology company focused on the discovery and development of differentiated monoclonal antibody therapies for the treatment of cancer and inflammatory and neurodegenerative diseases. The company operates within the biopharmaceutical and biotechnology industries, with a primary emphasis on immuno-oncology and central nervous system (CNS) disorders. Vaccinex’s core value proposition is its antibody discovery platform, which is designed to generate fully human monoclonal antibodies targeting novel biological pathways.

The company’s lead product candidate, pepinemab, is a monoclonal antibody targeting the semaphorin 4D (SEMA4D) pathway and represents the primary revenue-driving asset under development. Vaccinex serves pharmaceutical partners, clinical research institutions, and ultimately patients in specialized therapeutic areas with high unmet medical need. Founded in the late 1990s, the company evolved from a platform-focused antibody discovery enterprise into a clinical-stage developer with internally advanced drug candidates, culminating in its public listing on Nasdaq under the ticker VCNX.